Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEP1 for treatment of hospitalized COVID-19 patients
2020-005527-36Phase 2Active
- Sponsor
- Gesellschaft für Zelltherapie
- Start
- Jan 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2 trial of Human Ezrin Peptide 1 in coronavirus disease 2019 (COVID-19), sponsored by Gesellschaft für Zelltherapie. Primary endpoint: Time to clinical improvement. Started Jan 2021; status: active.
02
Drugs
Human Ezrin Peptide 1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005527-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005527-36.